Critical Analysis: ZIVO Bioscience (NASDAQ:ZIVO) & AlloVir (NASDAQ:ALVR)

Earnings and Valuation

This table compares ZIVO Bioscience and AlloVir”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15,850.00	4,159.37	-$7.78 million	($2.58)	-6.59
AlloVir	N/A	N/A	-$190.42 million	($20.23)	-0.24

ZIVO Bioscience has higher revenue and earnings than AlloVir. ZIVO Bioscience is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ZIVO Bioscience and AlloVir’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
AlloVir	N/A	-71.03%	-61.27%

Risk & Volatility

ZIVO Bioscience has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Institutional & Insider Ownership

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

ZIVO Bioscience beats AlloVir on 5 of the 9 factors compared between the two stocks.

About ZIVO Bioscience

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

About AlloVir

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm’s technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.